history
TOP>Corporate Information>History
1975 | September October |
The Company founded in Kobe, Japan Mikage Plant established at Higashinada-ku, Kobe |
---|---|---|
1976 | December | Development of purification method of Urokinase |
1977 | April | Research Laboratories established at Higashinada-ku, Kobe |
1983 | October | Manufacture of Urokinase product and bulk approved |
1985 | January | Import of human Growth Hormone (hGH) approved in Japan |
1986 | June December |
Seishin Plant established at Nishi-ku, Kobe Research Institute established at Nishi-ku, Kobe |
1992 | October | IPO (listed on the over-the-counter stock market in Japan) |
1993 | April October |
Manufacture of recombinant hGH product, Growject® Inj. 4IU, approved Research Laboratories established in northwest Kobe |
1994 | March | Manufacture of Ulinastatin bulk substance approved |
1995 | March | Listed on the Second Section of the Osaka Securities Exchange |
1997 | October | Alliance established with Mochida Pharmaceutical Co., Ltd. for supply of urine-derived products. |
1999 | January AprilOctober December |
Alliance established with Sumitomo Pharmaceuticals Co., Ltd. (current Dainippon Sumitomo Pharmaceuticals Co., Ltd.) for co-marketing of Growject® Inj. 4IU Manufacture of Macrophage Colony Stimulating Factor, Leucoprol®, started Marketing approval of Growject® 8mg Growject® approval expanded for Turner indication |
2000 | May July |
Kobe Plant established in northwest Kobe Growject® 8mg and Growject Pen launched |
2003 | August | Alliance established with Osiris Therapeutics, Inc. (USA) for its technology on the use and manufacture of human mesenchymal stem cells |
2008 | April | Murotani Plant established at northwest Kobe |
2009 | July | Growject® approval expanded for adult growth hormone deficiency |
2010 | January | Marketing approval of “Epoetin alfa BS Inj. JCR” obtained in Japan for treatment of renal anemia |
2011 | March | Listed on the Second Section of the Tokyo Stock Exchange |
2012 | August | Growject® approval expanded for short stature associated with small for gestational age |
2013 | May November |
Kobe API Plant established at northwest Kobe Listed on the First Section of the Tokyo Stock Exchange |
2014 | January | Japanese corporate name changed to "JCRファーマ" |
2015 | September | Marketing approval of TEMCELL® HS Inj., The first Allogeneic Regenerative Medicine in Japan |
2016 | April August |
Clinical Trial Material Manufacturing Center and Cell Processing Center established at northwest Kobe Marketing approval for a new liquid formulation of Growject® |
2017 | September | Business and Capital Alliance agreement conducted with MEDIPAL HOLDINGS CORPORATION |
2018 | January September |
JCR USA, Inc. established Marketing Approval of “Agalsidase Beta BS I.V. Infusion JCR” for Fabry disease |
2019 | September | Marketing Approval of “Darbepoetin Alfa BS Injection JCR”, a Long-Acting Erythropoiesis-Stimulating Agent. |
2020 | April September |
Acquire ArmaGen, Inc. JCR DO BRASIL FARMACÊUTICOS IMPORTAÇÃO E EXPORTAÇÃO LTDA. began business activities. |
2021 | January March |
Bioresearch Center has initiated operation at northwest Kobe Marketing Approval of “IZCARGO®” for Mucopolysaccharidosis type II |
2022 |
April September October November |
Transition to the Prime Market in the Tokyo Stock Exchange New Market Segments JCR Europe B.V. began business activities. AlliedCel Corporation established Kobe Science Park Center established at northwest Kobe |